SCHEMBL6826296

SCHEMBL6826296

Cc1ccsc1-c1[nH]c2ccc(Cl)cc2c1C1=NCCN1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 2/20 0.55
CCNB2 O95067 2/20 0.43
CDK1 P06493 2/20 0.43
CCNB1 P14635 2/20 0.43
GSK3B P49841 2/20 0.43
CDK5 Q00535 2/20 0.43
CDK5R1 Q15078 2/20 0.43
CCNB3 Q8WWL7 2/20 0.43
LMNA P02545 3/20 0.37
RECQL P46063 1/20 0.37
MAPT P10636 1/20 0.37
HTR1B P28222 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR7 P34969 1/20 0.37
HTR3A P46098 1/20 0.37
HTR6 P50406 1/20 0.37
ATP4A P20648 1/20 0.36
ATP4B P51164 1/20 0.36
MAP3K14 Q99558 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6821391 0.80 NISCH (0.53) NISCHCCNB2CDK1CCNB1GSK3B
SCHEMBL6825016 0.79 NISCH (0.51) NISCHLMNARECQLPTGS2CSF1R
Hydrochloric Acid SCHEMBL7735533 0.79 NISCH (0.52) NISCHCCNB2CDK1CCNB1GSK3B
SCHEMBL6824110 0.79 NISCH (0.48) NISCHLMNARECQLMAPTHTR1B
SCHEMBL6824809 0.79 LMNA (0.44) NISCHLMNARECQLMAPTHTR1B
SCHEMBL6825117 0.79 ATP4A (0.39) NISCHLMNARECQLMAPTHTR1B
SCHEMBL6824744 0.79 NISCH (0.45) NISCHLMNARECQLMAPTHTR1B
SCHEMBL6823645 0.78 LMNA (0.55) NISCHLMNARECQLHTR6PTGS2
Hydrochloric Acid SCHEMBL7736320 0.78 NISCH (0.50) NISCHLMNARECQLHTR2AHTR2C
SCHEMBL6820911 0.78 HTR6 (0.53) LMNARECQLMAPTHTR1BHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US claimed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP claimed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US claimed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO claimed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP claimed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R NISCH 277/4885CCNB2 4213/4885CDK1 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.